Skip to content
OpenCapital
Get started

Pacific Biosciences of California PACB Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss

Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies

PNC Financial Services logo
PNC Financial ServicesPNC
$73.15B+10.8%
BK
BKBK
$107.6B+9.7%
OceanFirst Financial logo
OceanFirst FinancialOCFC
$1.19B—
American International Group logo
American International GroupAIG
$71.9B+6.0%
State Street logo
State StreetSTT
$71.67B+6.3%
Eagle Bancorp logo
Eagle BancorpEGBN
$930.31M-23.4%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Pacific Biosciences of California (PACB) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $276.11M in Q1 2026.
How has Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss decreased by 19.4% year-over-year, from $342.73M to $276.11M.
What is the long-term trend for Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Over 3 years (2022 to 2025), Pacific Biosciences of California's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a -28.9% compound annual growth rate (CAGR), from $777.08M to $279.05M.